is 510(k) cleared and CE marked. Prosigna is available to healthcare professionals in the United States, in markets that recognize the CE mark, and/or in which Prosigna is registered.
Recognized as one of
Top 10 Innovations of 2013
This site is intended for US residents only.
Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From ABCSG-8 (
NanoString launches Prosigna Patient Support to help patients gain access to Prosigna.
Download the enrollment form today
Analytical validation study shows precision and reproducibility of PAM50-based Prosigna (
Study confirms ability of the Prosigna assay to assess risk of late distant recurrence
ABCSG-8 Clinical Validation Study (
Top Ten Innovations of 2013
Prognostic factors in late recurrence (
TransATAC Clinical Validation Study (
Managing patients with
early-stage breast cancer…
…begins with a highly
accurate assessment of risk
Mastering the science
of tumor biology
uses the PAM50 gene
signature to translate tumor
biology into your patient's individualized
Learn about PAM50 >
Advanced technology generates precise,
reproducible prognostic information in
local qualified laboratories.
you can trust
your patient's 10-year risk
of distant recurrence.
Clinical validation data >
© 2014 NanoString Technologies, Inc. All rights reserved. NanoString, the NanoString Technologies logo, nCounter, Prosigna and the Prosigna logo are trademarks and/or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
Terms of Sale
back to top